NR4A1 is overexpressed in RMS and correlates with expression of PAX3-FOXO1 in ARMS patients and treatment with synthetic CDIMs that are NR4A1 antagonists are highly effective in both cell culture and in vivo studies. This evidence concerns the gene NR4A1 and alveolar rhabdomyosarcoma.